Urogen Pharma Drug Patent Portfolio
Urogen Pharma owns 2 orange book drugs protected by 4 US patents Given below is the list of Urogen Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12268745 | Material and method for treating internal cavities | 20 Jan, 2031 | Active |
| US9040074 | Material and method for treating internal cavities | 20 Jan, 2031 | Active |
| US9950069 | Material and method for treating internal cavities | 20 Jan, 2031 | Active |
| US10039832 | 20 Jan, 2031 | Active |
Latest Legal Activities on Urogen Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Urogen Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 17 Nov, 2022 | US9040074 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 13 Oct, 2021 | US9950069 |
| Post Issue Communication - Certificate of Correction | 24 Jun, 2019 | US9040074 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 19 Nov, 2018 | US9040074 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 24 Apr, 2018 | US9950069 |
|
Recordation of Patent Grant Mailed
Critical
| 24 Apr, 2018 | US9950069 |
|
Email Notification
Critical
| 05 Apr, 2018 | US9950069 |
|
Issue Notification Mailed
Critical
| 04 Apr, 2018 | US9950069 |
|
Application Is Considered Ready for Issue
Critical
| 19 Mar, 2018 | US9950069 |
| Dispatch to FDC | 19 Mar, 2018 | US9950069 |
|
Issue Fee Payment Received
Critical
| 16 Mar, 2018 | US9950069 |
|
Issue Fee Payment Verified
Critical
| 16 Mar, 2018 | US9950069 |
| Supplemental Papers - Oath or Declaration | 26 Feb, 2018 | US9950069 |
|
Email Notification
Critical
| 01 Feb, 2018 | US9950069 |
|
Electronic Review
Critical
| 01 Feb, 2018 | US9950069 |
Urogen Pharma's Family Patents
Urogen Pharma Drug List
Given below is the complete list of Urogen Pharma's drugs and the patents protecting them.
1. Jelmyto
Jelmyto is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12268745 | Material and method for treating internal cavities |
20 Jan, 2031
(5 years from now)
| Active |
| US9040074 | Material and method for treating internal cavities |
20 Jan, 2031
(5 years from now)
| Active |
| US9950069 | Material and method for treating internal cavities |
20 Jan, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jelmyto's drug page
2. Zusduri
Zusduri is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039832 |
20 Jan, 2031
(5 years from now)
| Active | |
| US9040074 | Material and method for treating internal cavities |
20 Jan, 2031
(5 years from now)
| Active |
| US9950069 | Material and method for treating internal cavities |
20 Jan, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zusduri's drug page